» Articles » PMID: 30100187

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import

Abstract

Nuclear pore complexes (NPCs) regulate nuclear-cytoplasmic transport, transcription, and genome integrity in eukaryotic cells. However, their functional roles in cancer remain poorly understood. We interrogated the evolutionary transcriptomic landscape of NPC components, nucleoporins (Nups), from primary to advanced metastatic human prostate cancer (PC). Focused loss-of-function genetic screen of top-upregulated Nups in aggressive PC models identified POM121 as a key contributor to PC aggressiveness. Mechanistically, POM121 promoted PC progression by enhancing importin-dependent nuclear transport of key oncogenic (E2F1, MYC) and PC-specific (AR-GATA2) transcription factors, uncovering a pharmacologically targetable axis that, when inhibited, decreased tumor growth, restored standard therapy efficacy, and improved survival in patient-derived pre-clinical models. Our studies molecularly establish a role of NPCs in PC progression and give a rationale for NPC-regulated nuclear import targeting as a therapeutic strategy for lethal PC. These findings may have implications for understanding how NPC deregulation contributes to the pathogenesis of other tumor types.

Citing Articles

Nuclear envelope and chromatin choreography direct cellular differentiation.

Nair A, Khanna J, Kler J, Ragesh R, Sengupta K Nucleus. 2025; 16(1):2449520.

PMID: 39943681 PMC: 11834525. DOI: 10.1080/19491034.2024.2449520.


Identification of pyrimidine metabolism-based molecular subtypes and prognostic signature to predict immune landscape and guide clinical treatment in prostate cancer.

Yu Y, Xie X, Cai M, Hong Y, Ren Y, Kang X Ann Med. 2025; 57(1):2449584.

PMID: 39803822 PMC: 11731156. DOI: 10.1080/07853890.2025.2449584.


Mechanisms of Action of HSP110 and Its Cognate Family Members in Carcinogenesis.

Guo R, Wang R, Zhang W, Li Y, Wang Y, Wang H Onco Targets Ther. 2024; 17:977-989.

PMID: 39553399 PMC: 11568853. DOI: 10.2147/OTT.S496403.


The Potential of Nuclear Pore Complexes in Cancer Therapy.

Zaitsava H, Gachowska M, Bartoszewska E, Kmiecik A, Kulbacka J Molecules. 2024; 29(20).

PMID: 39459201 PMC: 11510365. DOI: 10.3390/molecules29204832.


Actin like 6A is a prognostic biomarker and associated with immune cell infiltration in cancers.

He Y, Li G, Wu Y, Cai N, Chen Z, Mei B Discov Oncol. 2024; 15(1):503.

PMID: 39333441 PMC: 11436596. DOI: 10.1007/s12672-024-01388-0.


References
1.
Zong Y, Goldstein A . Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol. 2012; 10(2):90-8. DOI: 10.1038/nrurol.2012.237. View

2.
Yu D, Thomas-Tikhonenko A . A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene. 2002; 21(12):1922-7. DOI: 10.1038/sj.onc.1205244. View

3.
Pascual-Garcia P, Capelson M . Nuclear pores as versatile platforms for gene regulation. Curr Opin Genet Dev. 2014; 25:110-7. DOI: 10.1016/j.gde.2013.12.009. View

4.
Kohler A, Hurt E . Gene regulation by nucleoporins and links to cancer. Mol Cell. 2010; 38(1):6-15. DOI: 10.1016/j.molcel.2010.01.040. View

5.
Barbieri C, Baca S, Lawrence M, Demichelis F, Blattner M, Theurillat J . Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012; 44(6):685-9. PMC: 3673022. DOI: 10.1038/ng.2279. View